Investment Opportunity – High-Scale, High-Return
This is a commercial-stage pharmaceutical company with proven demand, not a pre-revenue science project. Capital will accelerate production capacity and global commercialisation.
Seeking investments for equity in $100k packets. Rapid High Returns.
This is a commercial-stage pharmaceutical company with proven demand, not a pre-revenue science project. Capital will accelerate production capacity and global commercialisation.
Key Highlights
- A$8.5 million in verified historical revenue with exceptional customer retention
- 90% margin and recurring monthly consumable model
- Newly lodged foundational patent protecting proprietary formulation technology
- Clear path to automated Australian manufacturing scale-up
Scale potential:
Capturing just 1% of the addressable US market could generate around A$500 million in monthly revenue.
Investor return profile:
Dual-track opportunity with potential early cash dividends plus primary exit via strategic pharmaceutical acquisition or IPO. Management targets 25x–100x returns on each $100,000 investment packet.
Please email to request the full confidential prospectus.